via blogs.forbes.com
David Graham's study, if confirmed in another data set, could offer the FDA another lawyerly exit. Both Avandia and Actos cause heart failure, a weakening of the heart muscle, but in Graham's study Avandia was worse. That could give the FDA a reason to restrict its use or remove it from the market without ever admitting a mistake in its handling of the heart attack data.
No comments:
Post a Comment